CellaraRx provides a single‑cell tumor analysis platform that predicts a cancer patient’s response to specific therapies before clinical trial enrollment. By mapping treatment‑resistant cells and key cell types within tumors, it helps drug developers select appropriate trial participants, reducing failure rates and accelerating FDA approval timelines, while giving patients faster access to effective treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer clinical trials often fail because patients are enrolled without precise knowledge of tumor heterogeneity, leading to mismatched treatment responses and diluted drug efficacy signals.
Solution
CellaraRx offers a single‑cell genomic platform that profiles tumor cells at high resolution to identify treatment‑resistant subpopulations and their spatial distribution within the tumor microenvironment. By integrating this data with predictive analytics, the service forecasts a patient’s likelihood of responding to a specific investigational therapy before trial enrollment. Drug developers can therefore select cohorts enriched for likely responders, reducing late‑stage trial failures and accelerating development timelines. The approach also supports more efficient capital allocation for investors and provides patients faster access to effective treatments.
Target Audience
Primary customers are pharmaceutical companies and biotech firms conducting oncology clinical trials, as well as contract research organizations that manage patient enrollment and trial design.
Features
- Single‑cell RNA sequencing combined with spatial transcriptomics to map resistant cell types and their locations within tumor tissue
- Machine‑learning models that predict individual patient response probabilities for specific investigational drugs
- Automated cohort selection reports that rank patients by predicted benefit for inclusion in clinical trial arms
- Integration with existing trial management workflows via secure data export and API connectivity
- Compliance with clinical data privacy standards and end‑to‑end encryption for patient genomic information